EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Empagliflozin Adjunct With Insulin Pump Therapy Enhanced Glycemic Control and β-Cell Function in Patients With Long-Standing Type 2 Diabetes

Soobong Choi

AACE Endocrinology and Diabetes · 2026-04

DOI: 10.1016/j.aed.2026.03.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AACE Endocrinology and Diabetes, 2026-04. Verfasst von Soobong Choi. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Empagliflozin, a selective sodium-glucose cotransporter 2 inhibitor, improves glycemic control and insulin resistance in type 2 diabetes (T2D). This study evaluated the effectiveness of adjunct empagliflozin on glycemic control and β-cell function in patients with long-standing, inadequately controlled T2D despite insulin pump therapy.

Methods

In this single-center observational study, 103 patients (mean age 61.8 years; diabetes duration 17.8 years; pump duration 4.0 years) with inadequate control (HbA1c 6.6–14.3%) received 10 mg once-daily empagliflozin for six months. The primary endpoint was the change in HbA1c from baseline. Secondary endpoints included changes in C-peptidogenic index, Matsuda index (MI), disposition index (DI), total daily insulin dose (TDD), BMI, and serum creatinine.

Results

Data from 103 patients (mean follow-up 5.8 months) were analyzed. HbA1c significantly decreased from 7.82 ± 1.14% at baseline to 6.98 ± 0.92% (p < 0.001). β-cell function, assessed via the C-peptidogenic index and DI, significantly increased (p < 0.05), while TDD significantly decreased (p < 0.05). BMI and serum creatinine remained unchanged throughout the observation period. No DKA or frequent hypoglycemia occurred.

Conclusion

Adjunctive once-daily 10 mg empagliflozin significantly improved glycemic control and β-cell function while reducing total insulin requirements in patients with long-standing T2D inadequately controlled by insulin pump therapy alone. Notably, these benefits were achieved without significant changes in BMI or renal function.

Zitieren

APA

Choi, S. (2026). Empagliflozin Adjunct With Insulin Pump Therapy Enhanced Glycemic Control and β-Cell Function in Patients With Long-Standing Type 2 Diabetes. AACE Endocrinology and Diabetes. https://doi.org/10.1016/j.aed.2026.03.010

Vancouver

Choi S. Empagliflozin Adjunct With Insulin Pump Therapy Enhanced Glycemic Control and β-Cell Function in Patients With Long-Standing Type 2 Diabetes. AACE Endocrinology and Diabetes. 2026. doi:10.1016/j.aed.2026.03.010

BibTeX
@article{Choi2026,
  author = {Choi, Soobong},
  title = {Empagliflozin Adjunct With Insulin Pump Therapy Enhanced Glycemic Control and β-Cell Function in Patients With Long-Standing Type 2 Diabetes},
  journal = {AACE Endocrinology and Diabetes},
  year = {2026},
  doi = {10.1016/j.aed.2026.03.010}
}
Kostenlos starten →